Smart Hepatology: The Emerging Role of Artificial Intelligence and Digital Health in Viral Hepatitis Management.

Dr.C. Renuka Thejeshwini[1], Shaik Fijeeya[2] S.K. Samrin[3], Ramanadula Jessica[4],

[1]Associate Professor, Dr.K.V. Subba Reddy Institute Of Pharmacy, Dupadu, Kurnool.

[2]PharmD V Year, Dr.K.V. Subba Reddy Institute Of Pharmacy, Dupadu,Kurnool.

[3]Pharm D IV year, Dr.K.V. Subba Reddy Institute Of Pharmacy,Dupadu, Kurnool.

[4]PharmD V year, Dr.K.V. Subba Reddy Institute Of Pharmacy, Kurnool.

Corresponding author: shaikfijeeya24@gmail.com
Doi: https://doi.org/10.5281/zenodo.22686714
Received: 15 August 2026
Accepted: 07 September 2026

Abstract

Background: Hepatocellular carcinoma, cirrhosis, liver failure, and liver-related mortality are all greatly increased by viral hepatitis, which continues to be a major worldwide health concern. Effective illness management is still hampered by delayed diagnosis, restricted access to specialized care, and insufficient long-term surveillance, despite advancements in vaccine and antiviral therapy. By facilitating early diagnosis, individualized treatment, and ongoing patient monitoring, emerging technologies like artificial intelligence (AI) and digital health have the potential to revolutionize hepatology. The purpose of this review is to assess the growing importance of digital health and artificial intelligence technologies in viral hepatitis screening, diagnosis, prognosis, treatment planning, and long-term management.

Methods: To investigate the use of AI technologies, such as computer vision, machine learning, deep learning, and natural language processing, in the treatment of viral hepatitis, a thorough narrative review of the literature was carried out. Digital health advances like telehepatology, wearable technology, mobile health apps, electronic health records, and patient interaction platforms were also examined in the review.

Results: AI-driven systems showed great promise in combining clinical, laboratory, imaging, and genomic data to detect hepatocellular carcinoma, evaluate liver fibrosis and cirrhosis, forecast disease progression, and improve antiviral medication. Healthcare accessibility, patient adherence, remote monitoring, and continuity of care were all enhanced by digital health technologies. Precision medicine techniques and AI-assisted pharmacovigilance greatly improved therapeutic decision-making and customized patient care.

Obstacles and Prospects: Despite tremendous advancements, the application of AI in hepatology is constrained by issues with data quality, algorithm transparency, ethical considerations, legal frameworks, and inequities in healthcare infrastructure. To guarantee the safe and fair introduction of new technologies into standard clinical practice, further multicenter research, external validation, and interdisciplinary partnerships are crucial.

Conclusion: "Smart hepatology," which enables more precise, proactive, and patient-centered treatment of viral hepatitis, is being made possible by the convergence of digital health and artificial intelligence. To fully realize the potential of AI-driven healthcare solutions in hepatology, more research and technological advancements are required.

Keywords: digital health, hepatology, telehepatology, wearable technology, precision medicine, liver fibrosis, cirrhosis, hepatocellular carcinoma, and pharmacovigilance.

Introduction

Viral hepatitis burden worldwide

One of the principal causes of liver-related morbidity and mortality in the globe, viral hepatitis places a significant strain on public health initiatives and healthcare systems. Hepatitis B virus (HBV) and hepatitis C virus (HCV) chronic infections play a major role in the development of cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (1). Because liver illnesses cover a wide range of ailments, from acute viral hepatitis to advanced-stage cancers, comprehensive approaches to prevention, diagnosis, and therapy are required (1). Viral hepatitis still affects millions of people worldwide and is a leading cause of disability-adjusted life years and early mortality despite significant advancements in antiviral treatments and immunization campaigns (5). The demand for novel strategies to enhance patient outcomes and lower healthcare costs has increased due to the rising incidence of chronic liver disorders linked to HBV and HCV infections (2,4).

Impact of epidemiology on public health

Because viral hepatitis can proceed to chronic liver disease and is asymptomatic in the early stages of infection, it poses a serious threat to public health (1). Hepatic fibrosis, cirrhosis, and hepatocellular cancer are all primarily caused by chronic hepatitis B and hepatitis C infections (5). The global burden of hepatitis is still being reshaped by the shifting epidemiological patterns of liver disease, which are fueled by rising vaccination rates, easier access to direct-acting antivirals, and demographic shifts (5). Moreover, inadequate access to specialized care, delayed diagnosis, and differences in healthcare infrastructure continue to be significant obstacles to reaching global hepatitis elimination targets (3).

Conventional hepatitis treatment's limitations

Conventional methods of managing hepatitis mostly rely on clinical evaluation, laboratory testing, imaging methods, and medical knowledge, which may not always offer the best accuracy in forecasting the course of the illness (2). Inter-observer variability, delayed interpretation, and challenges integrating massive amounts of clinical data are common limitations of traditional diagnostic techniques (4). Diagnosis and treatment planning are sometimes complicated by the varied character of viral hepatitis and the intricacy of liver physiology (1). Furthermore, prompt management and long-term patient monitoring may be jeopardized by healthcare resource constraints and the scarcity of hepatology specialists (3).

The rise of digital health and artificial intelligence

By facilitating the analysis of extensive clinical datasets and enhancing diagnostic accuracy, recent developments in artificial intelligence (AI), machine learning (ML), deep learning (DL), and digital health technologies have revolutionized modern hepatology (2). Using radiological imaging, histology, and electronic health records, AI-based systems have shown promise in the identification of liver fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma (2).

Personalized hepatitis care and remote patient monitoring are now possible thanks to the integration of telemedicine, wearable technology, mobile health apps, and clinical decision-support systems (4).In hepatology practice, artificial intelligence algorithms are rapidly being employed to improve risk assessment, forecast treatment responses, and streamline healthcare operations (3,5).The expanding use of AI technology in healthcare contexts is nevertheless still hampered by issues with algorithm openness, data privacy, legal compliance, and ethical considerations (1,3).

Review objectives and scope

The goal of this review is to give a thorough overview of the developing role of digital health technology and artificial intelligence in the treatment of viral hepatitis. It focuses on the use of AI in long-term monitoring, prognostication, diagnosis, treatment planning, and disease screening (2). The assessment also looks at how digital

health tools, such as telemedicine, electronic health records, and mobile health platforms, might improve patient care and healthcare accessibility (4). In order to assist precision medicine and improve clinical outcomes, the study also addresses future directions, ethical issues, and existing problems in incorporating intelligent technology into hepatology practice (3).

2. Overview of viral hepatitis

2.1 Classification of Viral Hepatitis

The five hepatotropic viruses that cause viral hepatitis, group of infectious diseases with varying clinical manifestations modes of transmission, outcomes. Hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV) (6,7).HAV and HEV are mostly transmitted by the fecal–oral route, often through contaminated food and drink, and are usually associated with acute, selflimiting diseases (6).HBV and HCV, which are mostly transmitted by blood, sexual contact, and vertical transmission, are responsible for most chronic liver diseases worldwide (7,8). HDV is only found in HBV.Positive individuals and is associated with a faster onset of cirrhosis and liver failure (9).Because viral hepatitis is heterogeneous, tailored approaches to prevention, diagnosis, and treatment are needed to reduce the disease's burden and improve patient outcomes (10)

2.2 Epidemiology and Disease Burden

The morbidity and mortality associated with hepatocellular carcinoma (HCC) and chronic liver disease are greatly increased by viral hepatitis, which remains a major global public health concern (6,10).HBV and HCV infections affect hundreds of millions of people worldwide and account for a considerable portion of liver-related fatalities annually (10).Despite the introduction of effective immunizations against HAV and HBV as well as curative treatments for HCV infection, the burden of viral hepatitis persists due to inadequate screening, delayed diagnosis, and unequal access to healthcare (8). Hepatitis epidemiologies vary geographically, with a disproportionately high disease burden in low- and middle-income countries (9). Highrisk groups include those who inject drugs, get unscreened blood transfusions, work in the medical field, have multiple sexual partners, have impaired immune systems, and reside in areas with poor sanitation and medical facilities (6,7). However, low public awareness and socioeconomic inequities hinder efforts to eradicate viral hepatitis (8).

2.3 The Clinical Course and Complications

Viral hepatitis can cause severe acute hepatitis, asymptomatic infection, or chronic progressive liver damage (7). Acute hepatitis can cause fatigue, jaundice, nausea, stomach discomfort, and elevated liver enzymes, though many individuals show no symptoms in the early stages of infection (6). While HAV and HEV infections usually go away on their own, HBV and HCV infections can persist and cause chronic hepatitis in a considerable proportion of affected individuals (9). Chronic hepatitis often lasts for several decades and is characterized by persistent hepatic inflammation, fibrosis, and a progressive loss of liver function (10). Hepatic insufficiency, portal hypertension, and irreversible liver architectural distortion are the hallmarks of cirrhosis, which may eventually be brought on by persistent viral infection and chronic inflammation (8). Patients with cirrhosis are more prone to experience potentially lethal outcomes such as ascites, variceal hemorrhage, hepatic encephalopathy, and liver failure (7). Furthermore, hepatocellular carcinoma, one of the leading causes of cancer related death worldwide, is significantly increased by persistent HBV and HCV infections (10). Therefore, early identification and successful antiviral therapy are critical to controlling the development of the disease and improving survival outcomes (9).

2.4 Challenges with Conventional Hepatitis Therapy

Conventional hepatitis care mostly relies on laboratory testing, imaging methods, histological analysis, and specialized knowledge for diagnosis and therapy (7). However, delayed identification remains a significant worry since viral hepatitis frequently remains asymptomatic until late stages of liver disease occur (6). Limited access to hepatologists and specialized healthcare services, particularly in resource-poor locations, further impedes timely intervention and disease monitoring (8). Since long-term antiviral therapy and frequent follow up are necessary for optimal clinical outcomes, treatment adherence is another major obstacle (9).Healthcare systems

face substantial resource constraints, including inadequate infrastructure, a shortage of personnel, and financial barriers that restrict access to therapeutic and diagnostic treatments (10). These limitations underscore the need for advanced technologies such as artificial intelligence and digital health solutions to enhance screening, clinical decision-making, and long-term treatment of viral hepatitis (7,8).

3. The Fundamentals of Artificial Intelligence and Digital Health in Hepatology

3.1 Foundations of Artificial Intelligence

Artificial intelligence (AI) comprises a broad variety of computer techniques that enable machines to replicate human cognitive capabilities, such as learning, reasoning, and decision-making, to improve clinical practice in hepatology and facilitate the interpretation of complicated medical data (11,12). Machine learning (ML), an important subset of artificial intelligence, employs algorithms that may identify patterns in both organized and unstructured datasets to predict sickness outcomes, stratify patient risk, and optimize treatment approaches (11). Supervised, unsupervised, and reinforcement learning approaches have demonstrated great promise in the diagnosis and treatment of liver diseases, especially viral hepatitis (13). Deep learning (DL), a branch of machine learning, uses multilayered artificial neural networks to process large datasets and extract intricate information from medical pictures, histopathology slides, and lab records (12). Deep learning algorithms have shown improved performance in detecting cirrhosis, hepatocellular carcinoma, and liver fibrosis using radiological imaging and pathological specimens (11,13). The ability of these systems to automatically recognize complex patterns has reduced inter-observer variability and increased diagnosis accuracy in hepatology practice (10). Natural language processing (NLP), which enables computers to understand, assess, and generate human language from scientific literature, clinical documents, and discharge summaries, is another essential component of AI (12). By extracting clinically relevant information from electronic health data, NLP based techniques can assist in identifying individuals at risk for hepatitis-related complications and chronic liver disease (13). Furthermore, recent advancements in enormous language models have increased the possibilities for automated patient education and decision support in hematology (14).The primary objective of computer vision is to enable robots to assess and understand visual data from imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and histology slides (11). By integrating computer vision with deep learning frameworks, AI systems can accurately detect hepatic lesions, quantify fibrosis, and support the early diagnosis of liver illnesses (12). These technologies are now helpful tools for improving the efficiency and accuracy of diagnosis in clinical hepatology (12).

3.2 The Digital Health Ecosystem

A range of technologies designed to improve patient participation, healthcare delivery, and disease monitoring through digital platforms and networked systems make up the digital health ecosystem (12). Telemedicine has become an essential component of modern hepatology because it enables remote consultations, follow-up assessments, and multidisciplinary care, particularly for patients who reside in rural locations (13). The expansion of telehepatology services has improved access to specialized care and reduced barriers associated with travel and healthcare infrastructure limitations (14).

Mobile health (mHealth) technology, such as web-based platforms and smartphone applications, facilitate patient education, medication adherence, symptom tracking, and communication between patients and healthcare professionals (12). These tools are critical to the management of chronic illnesses because they encourage active patient participation and enable long-term viral hepatitis monitoring (11).Wearable systems with sensors allow continuous physiological monitoring by collecting real-time data on physical activity, sleep patterns, and other health indicators (13). Individualized treatment and early disease progression detection may be beneficial for those with long-term liver issues.(14)Electronic health records (EHRs) are an essential component of digital health systems as repositories of demographic information, test findings, imaging results, and treatment histories (12). AI-driven EHR data analysis can improve risk prediction, expedite clinical workflows, and improve diagnostic accuracy in hepatology practice (11). Clinical decision support systems (CDSSs) also employ AI and digital technology to enhance patient safety, maximize therapy options, and provide evidence-based recommendations (13).

3.3 Hepatology Practice and AI Integration

The use of artificial intelligence in hepatology has altered many aspects of managing liver disease, from prognosis and treatment planning to screening and diagnosis (11). AI technologies are quickly being incorporated into clinical processes to analyze imaging tests,laboratory parameters, and patient records to assist physicians in making timely and accurate decisions (12).ML algorithms have demonstrated promising outcomes in predicting the progression of fibrosis, therapeutic response, and risk of hepatocellular cancer in patients with viral hepatitis (13).Digital health technology also facilitates remote monitoring, improves patient-provider contact, and offers customized methods to sickness management (14). Despite these advancements, concerns about data quality, algorithm openness, regulatory approval, and ethical considerations continue to impact the mainstream use of AI in hepatology (12).

4. Artificial Intelligence in Hepatitis Virus Early Recognition and Diagnosis

4.1 AI-Powered Risk Prediction Models

Artificial intelligence has developed into a powerful tool for predicting the risk of developing viral hepatitis and its associated effects by integrating demographic, clinical, laboratory, and imaging data into predictive algorithms (15,16). By finding complex relationships between several factors that may not be apparent using conventional statistical techniques, machine learning models can aid in early identification and risk stratification in patients with viral hepatitis (16). These models are increasingly being utilized to predict the development of cirrhosis, fibrosis, hepatic decompensation, and hepatocellular cancer in individuals with chronic hepatitis B and hepatitis C infections (17). AI-based risk prediction systems allow clinicians to identify high-risk patients who require rapid treatment and close supervision (18). Additionally, prediction algorithms can constantly enhance their performance by iteratively learning from real-world clinical data, which increases their utility in hepatology practice (15).

4.2 Applying Machine Learning to Screening Initiatives

Machine learning approaches have significantly improved viral hepatitis screening systems by enabling the analysis of large-scale population datasets and electronic health records (16). Supervised learning algorithms can classify individuals according to their risk of acquiring hepatitis based on behavioral characteristics, medical history, test findings, and demographic characteristics (15). AI-powered screening methods reduce diagnosis delays and increase early detection rates by making it simpler to find asymptomatic individuals (17). These techniques are particularly helpful in low-resource settings when access to specialized care and cutting-edge diagnostic facilities is limited (18). Additionally, machine learning algorithms can optimize public health screening efforts by identifying people that would benefit most from targeted testing and preventive therapies (16). The use of AI in hepatitis screening programs has the potential to improve cost-effectiveness and support international efforts to eradicate hepatitis (17).

4.3 Laboratory Interpretation Tests for Liver Function Driven by AI

Artificial intelligence systems are increasingly being used to evaluate liver function tests, such as serum aminotransferases, bilirubin, albumin, and alkaline phosphatase levels, to enable early identification of liver injury and disease development (15). Machine learning algorithms can analyze long-term laboratory trends and identify subtle changes that may indicate declining liver function before clinical symptoms manifest (16). By incorporating several biochemical data, AI-based models provide clinicians with more accurate assessments of illness severity and prognosis (18).

Viral Signs

The interpretation of viral indicators, such as hepatitis B surface antigen, hepatitis B e antigen, hepatitis B virus DNA, hepatitis C virus RNA, and serological antibodies, can be enhanced by AI-assisted analytical tools (17). Machine learning algorithms can combine virological data with patient variables to predict disease activity, treatment response, and the likelihood of viral persistence (16). AI-driven methods also support individualized patient care by identifying individuals who are more prone to encounter issues and illness progression (15).

Examination of Biomarkers

Recent advances in artificial intelligence have led to the discovery and analysis of novel biomarkers associated with the development of viral hepatitis and liver disease (18). AI algorithms can evaluate large-scale genomic, proteomic, metabolomic, and transcriptome information to identify biomarkers that may improve prognostic assessment and diagnostic accuracy (17). Biomarker-based predictive models have demonstrated promising results in differentiating between intermediate disease and severe cirrhosis and fibrosis, allowing for customized therapy regimens (16). Combining machine learning techniques with biomarker analysis is a major step toward precision hepatology (15).

AI-Powered Liver Function Test (LFT) Interpretation

In contrast to traditional rule-based assessment, artificial intelligence (AI) has become a potent tool for interpreting liver function tests (LFTs), allowing doctors to detect liver illnesses more precisely and early. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, albumin, and prothrombin time are examples of laboratory parameters that are traditionally interpreted primarily using individual laboratory thresholds and physician expertise. In order to identify intricate associations that might not be seen through manual interpretation, AI systems combine these molecular markers with demographic traits, clinical history, imaging results, and electronic health records (EHRs) (27). Machine learning algorithms, such as random forests, support vector machines, gradient boosting models, and deep neural networks, have shown excellent predictive accuracy in differentiating between various liver diseases, including cirrhosis, hepatocellular carcinoma, viral hepatitis, liver fibrosis, metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic fatty liver disease (NAFLD). These models increase diagnostic sensitivity and specificity by analyzing minute changes in laboratory data instead of depending on solitary aberrant parameters (28). By forecasting mortality, liver-related complications, and disease progression, PMC +1 AI-driven laboratory interpretation also helps with risk stratification. Predictive models evaluate the evolution of fibrosis, portal hypertension, hepatic decompensation, and survival outcomes by combining serial LFT readings with inflammatory markers, platelet counts, and metabolic parameters. Clinicians can identify high-risk patients who need closer monitoring or early therapeutic intervention by using such longitudinal data (29,30).

4.4 AI in Radiological Assessment and Imaging Ultrasound

Ultrasonography is still one of the most widely used imaging modalities for evaluating liver disease, and artificial intelligence has greatly improved its diagnostic capabilities (18). Deep learning systems can detect hepatic abnormalities automatically, assess liver texture, and accurately identify cirrhosis and fibrosis symptoms (16). AI-assisted ultrasound interpretation reduces operator reliance and enhances diagnostic consistency across healthcare settings (17).

Computed Tomography Hepatic abnormalities, such as cirrhotic alterations and hepatocellular cancer, can now be automatically detected and characterized thanks to artificial intelligence applications in computed tomography (15). To increase diagnostic accuracy and risk prediction, machine learning methods can extract quantitative imaging features from CT scans and combine them with clinical data (18). For patients with persistent viral hepatitis, these technologies enable earlier detection and more efficient therapy planning (16).Imaging using Magnetic ResonanceAI-based techniques have improved the use of magnetic resonance imaging in hepatology, which offers comprehensive information about liver pathology and structure (17).With increased precision and repeatability, deepllearning algorithms can evaluate hepatic fibrosis, inflammation, steatosis, and tumor burden from MRI data (18).Additionally,AIassisted MRI interpretation promotes uniform clinical decisionmaking and lowers inter-observer variability (15).

Elastography

In patients with persistent viral hepatitis, elastography has become a significant noninvasive method for assessing liver fibrosis and stiffness (16). By combining imaging results with laboratory and clinical factors to produce more accurate estimations of disease severity, artificial intelligence can enhance elastographic assessment (17).AI-

enhanced elastography could make longterm disease monitoring easier and eliminate the need for invasive liver biopsies (18).

4.5 Using Deep Learning to Determine Fibrosis and Cirrhosis

Deep learning has revolutionized the detection and staging of cirrhosis and liver fibrosis by enabling automated interpretation of complex imaging and histology data (15). Convolutional neural networks have demonstrated remarkable accuracy in identifying fibrotic changes on CT, MRI, ultrasound, and digital pathology images (16). By spotting small patterns that are often difficult for human observers to detect, these algorithms improve diagnostic sensitivity and specificity (17). Furthermore, deep learning models provide early detection of individuals at risk for cirrhosis and hepatic decompensation, enabling timely intervention and improved patient care (18). Despite these advancements, there are still significant barriers to the widespread application of deep learning in hepatology, such as problems with data quality, model transparency, external validation, and ethical considerations (17). Further study and interdisciplinary cooperation will be required to fully exploit the potential of AI-driven diagnostic tools in the treatment of viral hepatitis (15,18).




Figure 1: Ai- Assisted Liver Imaging and Diagnosis

5. AI-Powered Personalized Management and Therapeutic Decision-Making

5.1 Predicting the Disease's Path

Artificial intelligence has developed into a groundbreaking tool for predicting the course of viral hepatitis in patients by integrating clinical, biochemical, imaging, and genetic data into predictive models (19,20). Machine learning algorithms can examine complex datasets to assess a patient's susceptibility to cirrhosis, hepatic decompensation, fibrosis progression, and hepatocellular carcinoma (20). Unlike traditional prognostic techniques, AI systems may continuously learn from real-world data and adapt to changing sickness patterns, enhancing projected accuracy over time (22). Predictive models based on longitudinal patient data and electronic health records allow clinicians to stratify patients based on the severity of their illness and optimize follow-up schedules (19). Early identification of high-risk individuals can provide timely therapeutic intervention and reduce the morbidity and mortality associated with chronic hepatitis infections (20).Recent research has shown that AI-driven prognostic tools can more correctly predict treatment responses and disease outcomes in chronic hepatitis B and hepatitis C infections than standard statistical models (19). By combining laboratory measures, viral markers, and imaging results, machine learning algorithms can generate customized risk scores that support therapeutic decision-making (22). These approaches offer more efficient resource allocation and customized disease treatment strategies in hepatology practice (20).

5.2 Precision Medicine and Viral Hepatitis

Precision medicine in hepatology, which aims to tailor medical treatments based on particular patient features, such as genetic profile, disease phenotype, lifestyle, and environmental factors, has been made possible by artificial intelligence (19). AI technology improves understanding of the disease heterogeneity in viral hepatitis by making it easier to examine large-scale datasets generated by proteomics, metabolomics, transcriptomics, and genomes (20).

Using machine learning algorithms to find molecular signatures associated with treatment-related issues, antiviral response, and illness progression, clinicians can develop customized treatment strategies (22). Additionally, the integration of multi-omics data with clinical information has increased the capacity to predict disease trajectories and optimize therapy outcomes (19). Precision medicine methods with AI support may potentially improve patient outcomes while lowering unnecessary interventions and medical costs (20).

Large language models and advanced AI systems have also demonstrated potential in the field of precision hepatology, enabling doctors examine complex patient data and synthesize scientific evidence (21). These technologies may offer customized treatment recommendations and support evidence-based practice in the treatment of viral hepatitis (22).

5.3 AI-Powered Treatment Option

Artificial intelligence is increasingly being utilized to guide treatment decisions by assessing patient-specific characteristics and predicting the most effective therapeutic options (19). Machine learning models can integrate demographics, liver function tests, viral load measurements, imaging results, and comorbidities to support customized therapy decisions (20). These techniques have shown promise in identifying individuals who are most likely to benefit from specific treatments and in determining when antiviral therapy should begin (22).

AI-assisted treatment selection tools may improve the care of patients with advanced liver disease by encouraging interdisciplinary decision-making and optimizing therapy planning (19). Decision-support systems powered by artificial intelligence can reduce clinical variability, provide evidence-based recommendations, and enhance treatment uniformity across healthcare settings (20). AI technology can also assist doctors in weighing the efficacy of a treatment against the danger of side effects, leading to safer and more effective care (21).Despite these




Figure 2: Machine Learning For Risk Predection and Treatment response

advancements, problems with data quality, algorithm transparency, and incorporating AI systems into routine healthcare procedures continue to impede general usage (22). Continuous validation and regulatory oversight will be necessary to ensure the reliability and security of AI-assisted therapy selection models (19).

5.4 Antiviral Response Prediction

Antiviral response prediction is still an important part of managing viral hepatitis since patient outcomes differ significantly (20). To forecast the possibility of therapeutic effectiveness and long-term virological response, artificial intelligence systems can examine host features, viral traits, laboratory results, and treatment histories

(19). Prediction models based on machine learning have shown promising outcomes in identifying patients who may need different treatment approaches and those who are likely to respond well to antiviral therapy (22).

By allowing clinicians to forecast resistance patterns, treatment failure, and disease recurrence, AI-driven prediction systems may help with customized treatment planning (20). The accuracy of antiviral response assessment has been further enhanced by the integration of proteomic and genomic data into predictive models (19). Large language models may also help medical practitioners by summarizing the most recent data on antiviral effectiveness and assisting with well-informed treatment choices (21).

Precision medicine, resource allocation, and long-term disease control in patients with chronic hepatitis B and hepatitis C infections are all significantly impacted by AI's capacity to predict treatment response (22).

5.5 Drug Safety Monitoring and Pharmacovigilance

Drug safety monitoring and pharmacovigilance are essential components of hepatitis management because antiviral therapies may be associated with adverse drug reactions, drug–drug interactions, and treatment-related complications (19). Artificial intelligence has the potential to strengthen pharmacovigilance systems by enabling real-time analysis of large volumes of clinical data from electronic health records, adverse event reporting systems, and patient-generated information (20).

Machine learning algorithms can detect patterns indicative of drug toxicity and identify previously unrecognized adverse effects, thereby improving medication safety and patient outcomes (22). AI-based pharmacovigilance platforms may also support early detection of hepatotoxicity and facilitate prompt intervention when adverse reactions occur (19). Furthermore, natural language processing techniques can extract relevant safety information from clinical notes, scientific literature, and pharmacovigilance databases, enhancing the efficiency of adverse event monitoring (21). Large language models have demonstrated promising applications in automating documentation, summarizing safety reports, and assisting clinicians in evaluating potential drug-related risks in patients with viral hepatitis (21). However, issues related to data privacy, algorithm bias, and regulatory compliance remain important considerations for the implementation of AI-driven pharmacovigilance systems (22). Addressing these challenges will be critical for ensuring the safe and effective integration of artificial intelligence into hepatitis care and therapeutic decision-making (19,20).

6. Innovations in Digital Health for Treating Viral Hepatitis

6.1 Models of Remote Care and Telehepatology:

By enabling remote consultations, follow up visits, and interdisciplinary care via digital platforms, telehepatology has become a crucial part of contemporary viral hepatitis management (24). Hepatology services are now more accessible because to the use of telemedicine, especially for patients who reside in underserved and rural areas with few specialized healthcare facilities (23).Without the need for frequent hospital visits, remote care models allow clinicians to assess therapy response, track disease progression, and deliver timely treatments (25).By providing automated risk assessment and customized therapy recommendations, the integration of artificial intelligence with telehepatology platforms has further improved clinical decisionmaking (24).Additionally, telehepatology helps patients with chronic viral hepatitis receive better care continuity, lower healthcare expenses, and less travel-related stress (23). The creation of virtual multidisciplinary teams of hepatologists, radiologists, pharmacists, and primary care physicians has been made easier by recent developments in communication technologies, which has improved coordinated patient care (25).

Additionally, AI powered remote monitoring systems can maximize the use of healthcare resources by identifying patients who need immediate medical attention (24). Despite these benefits, issues including poor internet access, obstacles to digital literacy, and worries about data security still prevent telehepatology services from being widely used (23).




Figure 3: Telepatology And Wearable Monitering

6.2 Applications for Mobile Health

By giving patients easy-to-use tools for medication adherence, illness management, and health education, mobile health (mHealth) applications have revolutionized the provision of healthcare services (24). People with viral hepatitis can track symptoms, keep an eye on treatment plans, get reminders, and interact in real time with medical specialists thanks to smartphone-based apps (25). By promoting active involvement in illness management and enhancing adherence to antiviral therapy, these tools promote patient-centered care (23).mHealth solutions powered by artificial intelligence are able to evaluate patient-generated data and offer tailored recommendations based on behavioral patterns and clinical state (24)Additionally, by providing evidence based information on disease prevention, lifestyle changes, and treatment options, mobile applications can support health education (25). Early detection of disease progression and prompt therapeutic intervention are now possible because to the incorporation of machine learning algorithms into mHealth systems (26). As a result, mobile health technologies offer a viable approach to enhancing long-term results in the treatment of viral hepatitis (24).

6.3 Patient Monitoring Wearable Technology

Advanced sensor-equipped wearable technology has drawn a lot of interest as a tool for personalized medicine and ongoing health monitoring (26). Real-time physiological data, such as heart rate, physical activity, sleep patterns, and other health markers pertinent to the management of chronic diseases, can be gathered by devices such smartwatches, fitness trackers, and biosensors (25). Large amounts of patient-generated data can be analyzed and early identification of clinically significant changes is supported by the integration of wearable technology with artificial intelligence algorithms (24).

By offering information on treatment compliance, physical functioning, and general health condition, wearable technology in hepatology may make it easier to remotely monitor patients with chronic viral hepatitis (25). Proactive interventions are made possible by AI-powered analytics, which may detect minute changes in physiological indicators that might point to the advancement of a disease or consequences from therapy (26). Additionally, the use of wearable-derived digital indicators could lead to future management techniques that are more accurate and customized (24). Despite the many advantages of wearable technology, issues with long-term usability, patient privacy, and device accuracy continue to be significant concerns (25).

6.4 Data Integration and Electronic Health Records

Because they allow for the systematic storing and retrieval of patient data, including laboratory results, imaging studies, treatment histories, and clinical notes, electronic health records (EHRs) are an essential part of the digital health ecosystem (24). Large-scale EHR databases are now accessible, opening up new possibilities for artificial

intelligence applications in viral hepatitis treatment and hepatology (25). By processing and integrating heterogeneous clinical data from many sources, machine learning algorithms can enhance diagnostic precision and facilitate evidence-based decision-making (23).

Risk prediction, clinical documentation automation, and the identification of patients who can benefit from focused interventions are all made possible by AI-assisted EHR analysis (24). Comprehensive monitoring of patient outcomes over time is made possible by data integration across healthcare systems, which also improves communication between medical personnel (25). Additionally, in hepatology practice, interoperability across EHR platforms and digital health technology can enhance care coordination and maximize resource use (23). However, problems with cybersecurity, standardization, and data quality still pose obstacles to the successful deployment of AI-enabled EHR systems (24).




Figure 4: Digital Health Ecosystem in Hepatology

6.5 Platforms for Patient Involvement and Self-Management

By enabling people to actively participate in their own healthcare, patient engagement and self-management platforms have grown in significance in the management of chronic diseases, including viral hepatitis (25). Patients can track their symptoms, receive medication reminders, access instructional materials, and communicate with healthcare practitioners via digital platforms (24). Increased patient satisfaction with healthcare services, better disease control, and better treatment adherence have all been linked to increased patient engagement (23).

By examining patient behavior, treatment trends, and health results, artificial intelligence technology can create customized recommendations for self-management techniques (25). AI-powered chatbots and virtual assistants may provide ongoing assistance, respond to patient questions, and encourage adherence to antiviral medication and lifestyle changes (24). Furthermore, constant monitoring and early detection of health issues are made possible by self-management platforms that are coupled with wearable technology and electronic health records (26). Patient-centered platforms are anticipated to become more crucial in enhancing healthcare accessibility and maximizing long-term results in viral hepatitis treatment as digital health technologies advance (25).

Research Deficit

There are still a number of significant research gaps in hepatology despite the quick development of digital health and artificial intelligence technology. The majority of AI models created for the treatment of viral hepatitis rely on historical data and are not externally validated across a range of demographics and medical environments. The generalizability and clinical use of these technologies are hampered by the scarcity of uniform, high-quality datasets and differences in clinical procedures. The long-term efficacy, cost-effectiveness, and practical impact of AI-driven therapies in enhancing patient outcomes and healthcare accessibility are also not well-documented.

The majority of current research has been on illness diagnosis and prediction; treatment adherence, patient involvement, pharmacovigilance, and the incorporation of wearable technology and mobile health platforms into standard hepatology practice have received relatively less attention. Additionally, ethical issues pertaining to algorithmic bias, data privacy, transparency, and regulatory approval are still not sufficiently addressed. Furthermore, the use of new technologies in the treatment of viral hepatitis is still in its early stages and needs more research through multicenter prospective studies. Examples of these technologies include explainable artificial intelligence, federated learning, massive language models, and digital twins.

The creation of reliable, comprehensible, and clinically validated AI models that can integrate multimodal data—such as imaging, genetics, electronic health records, and patient-generated information—should be the top priority for future research. To close these gaps and enable the safe and efficient application of intelligent healthcare systems in hepatology, cooperation between doctors, researchers, legislators, and technology developers will be crucial.

Conclusion

By facilitating early diagnosis, precise risk assessment, individualized treatment planning, and ongoing patient monitoring, artificial intelligence and digital health technologies are revolutionizing the field of viral hepatitis care. While digital health innovations like telemedicine, wearable technology, mobile health apps, and electronic health records have increased access to care and improved patient engagement, advances in machine learning, deep learning, natural language processing, and computer vision have shown considerable promise in improving the detection of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

By assisting with customized treatment decision making, anticipating antiviral responses, and improving pharmacovigilance, the use of AI into hepatology practice has exciting prospects for precision medicine. AIdriven methods may also maximize healthcare resources, shorten diagnostic wait times, and support international initiatives to eradicate viral hepatitis as a hazard to public health. But issues with data quality, interoperability, algorithm transparency, ethics, and legal frameworks still prevent these technologies from being widely used. To ensure fair and efficient healthcare delivery, it will be essential to address these obstacles through interdisciplinary cooperation, standardized validation techniques, and patient-centered implementation. In conclusion, "smart hepatology" has emerged as a result of the convergence of digital health and artificial intelligence, opening the door to more proactive, accurate, and easily accessible treatment for viral hepatitis. To fully utilize these technologies and influence the direction of hepatology in the age of digital medicine, more research and innovation will be necessary.

References

1)Bal T. A New Tool for the Diagnosis and Management of Viral Hepatitis: Artificial Intelligence. Viral Hepat J. 2024;30(1):1–6.

2)Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know. J Clin Exp Hepatol. 2026;16(1):103183.

3)Morel SMG, Wu S, Kendall TJ, Guha IN, Fallowfield JA, et al. Opportunities and Challenges of Artificial Intelligence in Hepatology. Npj Gut Liver. 2026;3:3.

4)Eskandar K. Artificial Intelligence in Hepatology: A Comprehensive Scoping Review of Clinical Applications, Challenges, and Future Directions. iLIVER. 2025;4(4):100205.

5)Zhang X, Wong GLH, Yip TCF. The Role of Artificial Intelligence in the Management of Liver Diseases. Hepatol Commun. 2025;9:e70022.

6)Bal T. A New Tool for the Diagnosis and Management of Viral Hepatitis: Artificial Intelligence. Viral Hepat J. 2024;30(1):1–6.

7)Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know. J Clin Exp Hepatol. 2026;16(1):103183.

8)Morel SMG, Wu S, Kendall TJ, Guha IN, Fallowfield JA, et al. Opportunities and Challenges of Artificial Intelligence in Hepatology. Npj Gut Liver. 2026;3:3.

9)Eskandar K. Artificial Intelligence in Hepatology: A Comprehensive Scoping Review of Clinical Applications, Challenges, and Future Directions. iLIVER. 2025;4(4):100205.

10)Zhang X, Wong GLH, Yip TCF. The Role of Artificial Intelligence in the Management of Liver Diseases. Hepatol Commun. 2025;9:e70022.

11)Cammà C, Cabibbo G, Enea M, et al. The Application of Artificial Intelligence in Hepatology: A Systematic Review. Dig Liver Dis. 2021;53(10):1247–1254.

12)Suenghataiphorn T, Tribuddharat N, Danpanichkul P, Kulthamrongsri N. Large Language Models in Hepatology: A Systematic Review. Hepatology Forum. 2026.

13)Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Challenges and Future Perspectives for Artificial Intelligence in Hepatology: Breaking Barriers for Better Care. J Clin Exp Hepatol. 2025.

14)Mak LY, Huang DQ. Novel Insights into Chronic HBV Infection. Nat Rev Gastroenterol Hepatol. 2026;23:122–123

15. Bal T. A New Tool for the Diagnosis and Management of Viral Hepatitis: Artificial Intelligence. Viral Hepat J. 2024;30(1):1–6.

16. Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know. J Clin Exp Hepatol. 2026;16(1):103183.

17. Morel SMG, Wu S, Kendall TJ, Guha IN, Fallowfield JA, et al. Opportunities and Challenges of Artificial Intelligence in Hepatology. Npj Gut Liver. 2026;3:3.

18. Eskandar K. Artificial Intelligence in Hepatology: A Comprehensive Scoping Review of Clinical Applications, Challenges, and Future Directions. iLIVER. 2025;4(4):100205.

19. Zhang X, Wong GLH, Yip TCF. The Role of Artificial Intelligence in the Management of Liver Diseases. Hepatol Commun. 2025;9:e70022.

20. Cammà C, Cabibbo G, Enea M, et al. The Application of Artificial Intelligence in Hepatology: A Systematic Review. Dig Liver Dis. 2021;53(10):1247–1254.

21. Suenghataiphorn T, Tribuddharat N, Danpanichkul P, Kulthamrongsri N. Large Language Models in Hepatology: A Systematic Review. Hepatology Forum. 2026.

22. Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Challenges and Future Perspectives for Artificial Intelligence in Hepatology: Breaking Barriers for Better Care. J Clin Exp Hepatol. 2025.

23. Mak LY, Huang DQ. Novel Insights into Chronic HBV Infection. Nat Rev Gastroenterol Hepatol. 2026;23:122–123.

24. Gao B, Duan W. The Current Status and Future Directions of Artificial Intelligence in the Prediction, Diagnosis, and Treatment of Liver Diseases. Digital Health. 2025;11:20552076251325418.

25. Mehrotra P, Vengadakrishnan K, Mehrotra P. Artificial Intelligence and Digital Biomarkers in Hepatology: Critical Perspectives, Emerging Evidence, and Future Directions. Cureus. 2025;17:e92639.

26. Krittanawong C, Rogers AJ, Johnson KW, Wang Z, Turakhia MP, Halperin JL, Narayan SM. Integration of Novel Monitoring Devices With Machine Learning Technology for Cardiovascular Care. Nat Rev Cardiol. 2021;18(2):75–91.

27.Eskandar K, et al. Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions. iLIVER. 2025;4(4):100205. ◆

PMC

28.Kannan S, et al. Artificial Intelligence and Digital Biomarkers in Hepatology: Critical Perspectives, Emerging Evidence, and Future Directions. Cureus. 2025.

29.Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317–1318.

30.Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380:1347–1358.